Lipe & Dalton Makes New Investment in Eli Lilly and Company (NYSE:LLY)

Lipe & Dalton purchased a new position in Eli Lilly and Company (NYSE:LLY) in the 4th quarter, HoldingsChannel reports. The fund purchased 45 shares of the company’s stock, valued at approximately $26,000.

Several other institutional investors have also modified their holdings of the business. Wealth Alliance grew its stake in shares of Eli Lilly and Company by 4.1% in the fourth quarter. Wealth Alliance now owns 7,221 shares of the company’s stock worth $4,209,000 after acquiring an additional 285 shares in the last quarter. Signet Financial Management LLC lifted its position in shares of Eli Lilly and Company by 0.5% during the 4th quarter. Signet Financial Management LLC now owns 10,467 shares of the company’s stock worth $6,101,000 after purchasing an additional 52 shares during the last quarter. Main Street Research LLC lifted its position in shares of Eli Lilly and Company by 3.4% during the 4th quarter. Main Street Research LLC now owns 3,132 shares of the company’s stock worth $1,826,000 after purchasing an additional 103 shares during the last quarter. Octavia Wealth Advisors LLC lifted its position in shares of Eli Lilly and Company by 43.6% during the 4th quarter. Octavia Wealth Advisors LLC now owns 734 shares of the company’s stock worth $428,000 after purchasing an additional 223 shares during the last quarter. Finally, Buffington Mohr McNeal lifted its position in shares of Eli Lilly and Company by 2.1% during the 4th quarter. Buffington Mohr McNeal now owns 3,003 shares of the company’s stock worth $1,751,000 after purchasing an additional 63 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 0.6 %

Shares of LLY traded down $4.21 on Tuesday, hitting $746.56. 2,568,597 shares of the stock traded hands, compared to its average volume of 3,085,273. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The firm has a market capitalization of $709.35 billion, a P/E ratio of 128.34, a P/E/G ratio of 1.65 and a beta of 0.34. The stock’s 50 day moving average is $762.68 and its two-hundred day moving average is $655.54. Eli Lilly and Company has a 1 year low of $367.35 and a 1 year high of $800.78.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.19. The business had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company’s quarterly revenue was up 28.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.09 earnings per share. As a group, sell-side analysts predict that Eli Lilly and Company will post 12.46 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Barclays lifted their price objective on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 7th. Morgan Stanley boosted their price target on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research report on Friday, February 16th. Wells Fargo & Company boosted their price target on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. BMO Capital Markets upped their target price on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a report on Wednesday, February 7th. Finally, The Goldman Sachs Group upped their target price on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a report on Thursday, April 11th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $728.05.

Insiders Place Their Bets

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of the stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the sale, the insider now owns 99,333,810 shares of the company’s stock, valued at $64,375,262,246.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.